HNN3.0

Project cooperationUpdated on 17 January 2026

Health economics & HTA expertise for Horizon Europe Cluster Health consortia, with a focus on rare and small-population settings.

Founder & Health Economist at Rare Disease Consulting

Athens, Greece

About

Rare Disease Consulting (RDC) offers health economics and Health Technology Assessment (HTA) expertise to Horizon Europe Cluster Health consortia.

RDC contributes health economic and HTA modelling for cost-effectiveness and long-term outcomes, burden-of-illness assessment, and analysis of affordability and health-system impact. The focus is on rare-disease and other small-population or high-uncertainty research settings, where evidence generation and evaluation pose particular methodological challenges.

RDC is interested in joining consortia preparing or implementing Horizon Europe Cluster Health proposals, contributing to evaluation, impact, and implementation-related work packages. Collaboration is sought with academic, clinical, SME, and patient-organisation partners involved in health research and innovation.

Topic

  • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
  • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-03: Building public trust and outreach in the life sciences
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
  • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
  • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)

Type

  • Partner seeks Consortium/Coordinator

Organisation

Rare Disease Consulting

Consultancy

Athens, Greece

Similar opportunities